Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Non Operating Income: 2015-2025

Historic Non Operating Income for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $2.8 million.

  • Voyager Therapeutics' Non Operating Income fell 41.72% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 20.10%. This contributed to the annual value of $18.9 million for FY2024, which is 61.63% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Non Operating Income is $2.8 million, which was down 14.52% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Non Operating Income registered a high of $4.9 million during Q2 2024, and its lowest value of -$1.6 million during Q2 2021.
  • Moreover, its 3-year median value for Non Operating Income was $3.4 million (2023), whereas its average is $3.7 million.
  • In the last 5 years, Voyager Therapeutics' Non Operating Income crashed by 627.67% in 2021 and then spiked by 5,912.90% in 2023.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Non Operating Income stood at $397,000 in 2021, then spiked by 140.05% to $953,000 in 2022, then skyrocketed by 230.95% to $3.2 million in 2023, then spiked by 39.38% to $4.4 million in 2024, then tumbled by 41.72% to $2.8 million in 2025.
  • Its Non Operating Income stands at $2.8 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.7 million for Q1 2025.